Q1 Earnings Forecast for NTLA Issued By William Blair

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Equities research analysts at William Blair issued their Q1 2026 earnings per share estimates for Intellia Therapeutics in a report issued on Wednesday, March 26th. William Blair analyst M. Minter expects that the company will post earnings per share of ($1.12) for the quarter. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.07) per share. William Blair also issued estimates for Intellia Therapeutics' Q3 2026 earnings at ($1.28) EPS and Q4 2026 earnings at ($1.35) EPS.

NTLA has been the topic of several other research reports. StockNews.com raised Intellia Therapeutics to a "sell" rating in a research note on Monday, March 3rd. Wedbush reissued a "neutral" rating and set a $10.00 price target (down previously from $14.00) on shares of Intellia Therapeutics in a research report on Friday, January 10th. Chardan Capital decreased their price objective on Intellia Therapeutics from $91.00 to $68.00 and set a "buy" rating for the company in a report on Friday, February 28th. Morgan Stanley lowered shares of Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and lowered their price objective for the stock from $56.00 to $11.00 in a research note on Monday, January 27th. Finally, Barclays cut their target price on shares of Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $37.56.

Remove Ads

Intellia Therapeutics Price Performance

NTLA stock traded down $1.01 during mid-day trading on Thursday, reaching $7.06. The company had a trading volume of 3,063,023 shares, compared to its average volume of 3,249,999. The firm has a 50 day moving average of $9.98 and a 200 day moving average of $13.72. Intellia Therapeutics has a 12 month low of $7.08 and a 12 month high of $28.18. The company has a market capitalization of $731.04 million, a PE ratio of -1.30 and a beta of 1.97.

Hedge Funds Weigh In On Intellia Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NTLA. Regeneron Pharmaceuticals Inc. purchased a new position in shares of Intellia Therapeutics in the fourth quarter worth about $43,177,000. Voloridge Investment Management LLC increased its holdings in Intellia Therapeutics by 226.8% in the fourth quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company's stock valued at $17,805,000 after buying an additional 1,059,751 shares in the last quarter. Contrarius Group Holdings Ltd acquired a new position in Intellia Therapeutics in the 4th quarter worth about $11,798,000. Two Sigma Advisers LP lifted its position in shares of Intellia Therapeutics by 94.5% during the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company's stock valued at $23,300,000 after buying an additional 970,700 shares in the last quarter. Finally, Two Sigma Investments LP lifted its position in shares of Intellia Therapeutics by 88.1% during the 4th quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company's stock valued at $21,498,000 after buying an additional 863,363 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company's stock.

Insiders Place Their Bets

In other news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders have sold 29,000 shares of company stock valued at $352,551. Insiders own 3.20% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.